750,000 Shares in Annexon, Inc. $ANNX Acquired by Ishara Investments LP

Ishara Investments LP acquired a new stake in Annexon, Inc. (NASDAQ:ANNX) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 750,000 shares of the company’s stock, valued at approximately $3,765,000. Annexon accounts for about 4.4% of Ishara Investments LP’s holdings, making the stock its 6th biggest position.

Other large investors also recently modified their holdings of the company. CIBC Bancorp USA Inc. purchased a new stake in shares of Annexon in the 3rd quarter valued at approximately $31,000. Engineers Gate Manager LP purchased a new stake in shares of Annexon in the 2nd quarter valued at approximately $32,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Annexon by 65.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock valued at $35,000 after purchasing an additional 2,785 shares during the last quarter. Savant Capital LLC purchased a new stake in shares of Annexon in the 3rd quarter valued at approximately $40,000. Finally, Landscape Capital Management L.L.C. purchased a new stake in shares of Annexon in the 4th quarter valued at approximately $50,000.

Insider Buying and Selling at Annexon

In related news, Director William H. Carson bought 8,000 shares of the stock in a transaction dated Monday, May 11th. The stock was acquired at an average price of $5.78 per share, for a total transaction of $46,240.00. Following the acquisition, the director owned 78,405 shares in the company, valued at approximately $453,180.90. This represents a 11.36% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Muneer A. Satter bought 613,497 shares of the stock in a transaction dated Thursday, May 28th. The stock was bought at an average price of $5.41 per share, with a total value of $3,319,018.77. Following the acquisition, the director owned 10,342,134 shares in the company, valued at approximately $55,950,944.94. This represents a 6.31% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders bought 629,497 shares of company stock valued at $3,414,859. Company insiders own 10.31% of the company’s stock.

Annexon Trading Up 9.3%

Shares of Annexon stock opened at $4.94 on Thursday. The company has a fifty day simple moving average of $5.55 and a 200-day simple moving average of $5.46. Annexon, Inc. has a 12-month low of $1.85 and a 12-month high of $7.18. The stock has a market cap of $809.37 million, a price-to-earnings ratio of -4.05 and a beta of 1.18.

Annexon (NASDAQ:ANNX) last issued its earnings results on Thursday, May 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.07. On average, analysts forecast that Annexon, Inc. will post -0.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Wall Street Zen raised shares of Annexon from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Annexon in a research report on Monday, April 20th. The Goldman Sachs Group assumed coverage on shares of Annexon in a research report on Tuesday, May 12th. They issued a “neutral” rating and a $7.00 price objective on the stock. Finally, Chardan Capital reissued a “buy” rating and issued a $16.00 price objective on shares of Annexon in a research report on Friday, March 20th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $16.00.

About Annexon

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.